ClinicalTrials.gg
RecruitingNCT03948438Updated Sep 21, 2022

Endoscopic Treatment for Zenker's Diverticulum

An observational study in Zenker Diverticulum, sponsored by Istituto Clinico Humanitas. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Istituto Clinico Humanitas · Observational

From the registry’s dates

  • Started Jan 2009; still recruiting 17 years 10 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Study summary

Zenker's diverticulum (ZD) is a rare benign condition, due to an acquired sac-like outpouching of the mucosa and submucosa layers originating from the pharyngoesophageal junction. Endoscopic techniques like flexible endoscopic septum division (FESD) or per-oral endoscopic septotomy (POES), represent a minimally invasive alternative to surgery or to rigid endoscopic procedure to treat ZD. The goal of the research will be to evaluate the safety of the procedures and to measure Zenker-symptom severity in all patients treated by endoscopic procedures.

02

Conditions studied

  • Zenker Diverticulum
03

In context

Lead sponsor

Istituto Clinico Humanitas is the lead sponsor of 279 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients affected by ZD and treated by endoscopic procedures.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with symptomatic ZD treated by endoscopic procedures

Exclusion criteria

Exclusion Criteria:

  • pregnancy and breastfeeding
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Interventions

  • ProcedureEndoscopic septotomy

    Patients will be placed in left lateral decubitus position, either in conscious sedation or under deep sedation with propofol or endotracheal intubation.The procedure will be performed with a flexible standard endoscope and started with initial endoscopic examination with suction of possible retained material insidethe diverticulum. An incision of the bridge between the ZD and the esophagus will be done (using one endoscopic procedure as POES or FESD or other)

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events

    Any complications as bleeding, perforation, others

    Time frame: 24 hours after the procedure

Secondary outcomes

  1. symptoms after the procedure

    The frequency of symptoms such as dysphagia, regurgitation, weight loss

    Time frame: up to 5 years

07

Study locations

1 of 1 sites recruiting
  • Humanitas Research Hospital
    Rozzano, 20089, Italy
    Recruiting
    • Alesandro Repici, MD · Contactalessandro.repici@hunimed.eu · 0039-02-82247493
    • Milena Di Leo, MD · Sub investigator
    • Roberta Maselli, PhD · Sub investigator
    • Piera A Galtieri, MD · Sub investigator
    • Elena Finati · Sub investigator
08

References and documents

Publications

  • Repici A, Cappello A, Spadaccini M, Nicoletti R, Carrara S, Fugazza A, Galtieri PA, Lamonaca L, Romana C, Badalamenti M, Di Leo M, Pellegatta G, Ferrara EC, Anderloni A, Maselli R. Cap-Assisted Endoscopic Septotomy of Zenker's Diverticulum: Early and Long-Term Outcomes. Am J Gastroenterol. 2021 Sep 1;116(9):1853-1858. doi: 10.14309/ajg.0000000000001356. PubMed 34236338 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03948438
Responsible party
Sponsor
First posted
May 14, 2019
Start date
Jan 1, 2009
Primary completion
Dec 30, 2028 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Sep 21, 2022

Study contacts

Alessandro Repici, Prof.
Contact
alessandro.repici@hunimed.eu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion